Searched for
IMMUNEEL THERAPEUTICS
GSK in talks to buy cancer biotech Nuvalent for more than $9 billionBritish drug giant GSK is reportedly in talks to acquire cancer drugmaker Nuvalent. The deal could be worth over nine billion dollars. Disc...- West Bengal's electronics factory push; Fed jitters hit TCSWest Bengal is exploring ways to expand electronics manufacturing under EMC 2.0. This and more in today's ETtech Top 5.
- Kiran Mazumdar-Shaw's Immuneel Therapeutics raises Rs 100 crore from Singularity AMC, Rainmatter, othersThe Bengaluru-based company makes CAR-T therapy, a form of cancer treatment where a patient’s own immune cells are taken out, trained in a ...
- Tata-backed MedTherapy claims CAR-T breakthrough with one-day productionTata Sons-backed biotech startup MedTherapy said it has developed a next-generation CAR-T cell therapy manufacturing platform that can redu...
- Homegrown cell, gene therapy pioneer ImmunoACT turns profitable in first year of opsImmunoAct, an Indian cell and gene therapy company, has achieved profitability in its first full year, generating ₹62 crore in revenue and ...
- China’s biotech is redrawing the global pharma map; what India can learnAmerican biggies are joining hands with Chinese companies. AbbVie signed a deal with Simcere Zaiming for a multiple myeloma treatment. Astr...
- Biocon urges government to exempt cancer, rare-disease drugs from tax in budgetIndia should eliminate tax on drugs for cancer treatment and chronic diseases, urged Biocon's chairperson Kiran Mazumdar-Shaw, ahead of the...
- Bengaluru company launches low-cost treatment for blood cancerImmuneel Therapeutics, co-founded by Kiran Mazumdar-Shaw, has introduced Qartemi, India's second CAR-T cell therapy, to treat B-cell Non-Ho...
- ETtech Deals Digest: Startup funding slips 22.5% to $70 million in July second week YoYStartups in Bengaluru raised $70 million in the second week of July, a 22.5% decrease from last year. Funds were raised mostly at the seed ...
- Difficult to scale up expensive therapy beyond a point: Kiran Mazumdar-ShawCAR-T therapies, previously not available in India, have shown promising results for patients who have exhausted all other means of treatme...
- Enzene Biosciences raises $50 million to expand ops in India, US marketsIn a press statement, Enzene said it would leverage the fresh funds to enhance its manufacturing capabilities and drive expansion in its co...
- Why Kiran Mazumdar-Shaw wants this Pulitzer-winner's 'immaculately researched' book to be prescribed in every high schoolThe Biocon boss says this book inspires the reader to delve deeper into the mysteries of cellular science.
- All diseases are cellular diseases: Dr Siddhartha MukherjeeRenowned oncologist, cancer researcher and Pulitzer Prize-winning author Dr Siddhartha Mukherjee’s latest book The Song of The Cell: An Exp...
- Why are investors shying away from biotech startups?Investors have largely been risk-averse when it comes to deep-funding biotech startups that have the potential to turn into billion-dollar ...
- RBI’s new mandate sparks confusion among fintechs; Foxconn may make EVs in IndiaThe regulator’s directive quickly sparked confusion and frustrations among fintech startups, which told us the RBI appears to be giving ban...
- LeadSquared is the latest SaaS unicorn; Matrix to raise $450M India fundLeadSquared raked in $153 million from WestBridge and others to join the unicorn club
- Immuneel Therapeutics raises $15 million in fundingImmuneel Therapeutics is working on developing its own pipeline of chimeric antigen receptor T-cell (CAR-T) therapies and other cellular im...
- Immuneel signs pact with Hospital Clínic de Barcelona to work on cancer therapyThe collaboration opens up opportunities for co-development of advanced assets to be deployed in Spain and India, said Immuneel in a press ...
Load More
